कृपया अन्य खोज का प्रयास करें
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company’s products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Joshua Cohen | 30 | 2013 | Co-Founder, Co-CEO & Director |
Justin Klee | 31 | 2013 | Co-Founder, Co-CEO & Director |
Rudolf Emile Tanzi | 63 | - | Chairman of The Scientific Advisory Board |
George Mclean Milne | 78 | 2015 | Independent Chairman of the Board |
Walter A. Gilbert | 90 | 2016 | Special Advisor & Member of Advisory Board |
Alan Edmund Walts | 61 | 2017 | Board Observer & Advisor |
Sasha H. Bakhru | - | - | Member of Scientific Advisory Board |
Paul R. Fonteyne | 61 | 2021 | Independent Director |
Daphne E. Quimi | 56 | 2021 | Independent Director |
Karen Mindy Firestone | 67 | 2023 | Independent Director |
Peter B. Finn | - | - | Company Secretary & Member of Scientific Advisory Board |
Bernhardt G. Zeiher | 60 | 2024 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है